Taiwan Targets Blood-Bag Production as China Steps Up Pressure
Taiwan aims to start producing its own blood bags — a key item for saving lives on the battlefield — adding to signs President Lai Ching-te is stepping up preparations for a potential conflict with China.
The Health Ministry has been working closely with other government agencies, including the National Security Council, to enhance Taiwan's medical preparedness for emergencies, Deputy Health Minister Lin Ching-yi told Bloomberg News. Strengthening domestic production capacity for key medical supplies, including blood bags, is a part of the strategy, she said, as was ensuring that imports of medical supplies were secure.
'The Covid-19 pandemic and the war in Ukraine have underscored the risks of relying solely on foreign sources for essential medicines and medical equipment,' Lin said. Ukraine's health-care resources have been strained during its fighting with Russia, leading to shortages of oxygen, medications and more.
Lai has made preparing the self-ruled archipelago of 23 million people for a possible conflict with China a central part of his policymaking since he took office a little more than a year ago. Last year, he held the first meeting of a civil defense committee that discussed ways to make sure key energy facilities and critical infrastructure can operate in a crisis.
China views Taiwan as part of its territory that must be brought under its control someday, by force if necessary. The People's Liberation Army has held an unprecedented amount of military exercises around Taiwan since Lai took over, underscoring its deep distrust of a leader it worries will formalize Taiwan's independence.
Officials in Taipei downplay the likelihood of a conflict with China anytime soon, though US Defense Secretary Pete Hegseth recently warned more urgency is needed to prepare for a potential People's Liberation Army invasion.
From at least last year, the US — Taipei's main military backer — started raising concern about the archipelago's blood reserves and distribution capabilities, according to Taiwanese officials familiar with the matter, who asked not to be identified discussing the sensitive matter.
Specific issues included whether Taiwan had enough electricity supplies and backup power systems for blood banks, one of the officials said. The US was also worried about adequate cold-chain logistics and storage, the person added.
In a report to lawmakers in March, the Defense Ministry in Taipei said that it planned to establish its first blood donation center by the end this year. A program to create a centrally managed blood supply system would be set up in 2026, it added.
Lin said Taiwan relies on imports for its supply of blood bags because that is cheaper than making them domestically. Blood bags are containers primarily made of medical-grade PVC that are used in the collection, storage and transfusion of blood. A ready supply is critical in wartime, and would help save the lives of soldiers in Taiwan's military, which is much smaller than China's.
Taiwan's National Security Council declined to comment on Tuesday on the push to improve medical preparedness.
Nan Ya Plastics Corp., a subsidiary of Taiwan's largest petrochemical conglomerate, Formosa Plastics Group, has built the archipelago's first blood bag factory near Taipei, Economic Daily News reported, citing a person at a firm that cooperates with Nan Ya Plastics on the plant.
It is in the process of applying for a certificate to produce the containers, EDN said in a separate report that cited comments Nan Ya Plastics chairman Wu Chia-chau made at an annual general meeting last week.
Nan Ya Plastics didn't immediately respond to a request for comment.
With assistance from Miaojung Lin.
This article was generated from an automated news agency feed without modifications to text.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
A shot of hope
New HIV medicine is powerful – but can everyone afford it? A new medicine called lenacapavir has just been approved in the US to help stop people from getting HIV, the virus that causes AIDS. That's big news! Even though fewer people are getting HIV today than in the 1990s, around 13 lakh (1.3 million) people still get infected every year around the world. Lenacapavir is special because you only need two shots a year – not a pill every day like older medicines. That's great for people who forget daily pills or feel embarrassed taking them. And it's almost 100% effective at stopping HIV in adults and teens. But there's a big problem: the cost. In the US, it sells for over ₹23 lakh a year! Even rich countries find that hard to afford. The company that makes it, Gilead, is working with more than 100 poorer countries to help them make cheaper versions. Still, many African countries where HIV is most common may struggle to get it to the people who need it most. Scientists have been trying to create a proper HIV vaccine for decades, but HIV keeps mutating – changing too fast for one shot to work. New mRNA vaccines (like the ones used for Covid) are being tested, but funding cuts in the US have slowed down this research. That's why lenacapavir gives us hope. But hope only works if everyone, everywhere, can afford it. Facebook Twitter Linkedin Email Disclaimer Views expressed above are the author's own.
Time of India
2 hours ago
- Time of India
Dose of hope
Times of India's Edit Page team comprises senior journalists with wide-ranging interests who debate and opine on the news and issues of the day. To really help, new HIV vax has to be made cheap A pill to treat multidrug-resistant HIV, lenacapavir, has been approved by US drug regulator FDA as a preventive vaccine. This is a huge deal – incidence of HIV may have declined since 1990s but even today about 13L people globally are infected by the virus every year. But its price is an obstacle. Sold for $28,218 per year in US, it's prohibitive even for high-income nations. Pharma company Gilead that manufactures lenacapavir has reportedly tied up with over 100 middle- and low-income countries for manufacture of generics pending approvals. But access likely will still be tricky for poorer African countries that bear the HIV burden. Drugs to prevent HIV transmission have been around almost a decade, but a daily dosage regimen makes these unreliable. People forget and there's the stigma/doubt in partners that a daily dose is preventive. Lenacapavir needs to be taken just twice a year. Its long-lasting effect in preventing infection – almost 100% in adults and adolescents – is thus the best bet today. Also because HIV research in US bears the additional burden of Trump administration's slashed funds. An effective vaccine for HIV has been elusive for decades because of its rapid mutations. Several mRNA vaccines, like those developed for Covid and considered the most promising, are in clinical trials. But since Jan, under Trump's health secretary Bob Kennedy Jr, NIH stopped funding hundreds of such HIV vaccine-related research. This is what makes repurposed lenacapavir a lifeline, provided it's made affordable. Facebook Twitter Linkedin Email This piece appeared as an editorial opinion in the print edition of The Times of India.
India Today
3 hours ago
- India Today
Health ministry probes AIIMS Bhopal over irregularities in medicine purchases
A team of officials from the Union Health Ministry visited AIIMS Bhopal to examine documents related to medicine procurement, following allegations by Bhopal MP Alok Sharma that the institute purchased medicines at inflated the matter was raised before the AIIMS Standing Committee on Finance during a meeting in Delhi. The central team arrived at AIIMS Bhopal on Thursday morning and examined documents related to the purchase of medicines. The team also met the Director of the institute and enquired about the purchase process. advertisement The institute has been accused of purchasing medicines directly without following the rules of the central government. In his complaint, Bhopal MP Alok Sharma mentioned that the prices of medicines purchased by AIIMS Bhopal are much more expensive than the AIIMS of other states. Sharma, who is also a member of the AIIMS standing committee, said that he had received a complaint that the injection of Gemcitabine was purchased by Bhopal AIIMS at Rs 2100 per piece, whereas it was purchased at Rs 425 by Raipur AIIMS of Chhattisgarh. Its price in Delhi AIIMS is Rs 285 per piece. The prices of other medicines were also found to be higher. "On May 15, a meeting of the AIIMS standing committee was held in New Delhi in the presence of Union health secretary Punya Salila Shrivastava. In the meeting, I complained regarding the high prices of medicines being purchased by AIIMS Bhopal. She assured me that an investigation will be conducted," said Sharma. advertisementHe also said that like other government hospitals, medicines are bought through tender in AIIMS. However, during the Covid-19 period, direct purchase of medicines was approved. "However, despite the end of the Covid-19 period, direct purchase of medicines continued and the figure of purchased medicines reached crores," he added. Must Watch
